

## Press Release



---

# Omega Pharma intends to buy back 2 million shares

## *17% sales growth in October 2007*

Nazareth, Belgium 21 November 2007 — The Board of Directors of Omega Pharma has decided to buy back up to 2 million of its own shares. In addition, the company has also reconfirmed the 2007 sales guidance of EUR 780-800 million, following the strong 17% growth of turnover in October.

### **Strong balance sheet supports value creation**

The balance sheet situation of Omega Pharma has been substantially strengthened as a direct consequence of the Arseus carve-out and IPO. The Arseus IPO has yielded Omega Pharma approximately EUR 270 million in additional resources. The remaining 24% participation in Arseus is also a valuable asset. Finally, Omega Pharma expects to post an extraordinary, positive accounting result of at least EUR 70 million for the current period.

### **Share buy-back program confirms confidence in achievability of ambitions**

The Board of Directors has decided to take advantage of the strengthened balance sheet to buy back 2 million of its own shares during the period ending with the Shareholders Meeting in May 2008. With this decision, the Board of Directors confirms the fundamental health of the business model and underlines its confidence in the achievability of its long-term ambitions and the strategic plan.

### **Strong start for the Fourth Quarter — 2007 Sales Guidance confirmed**

Backed by a strong 17% growth of turnover in the month of October 2007 (compared to October 2006), Omega Pharma hereby confirms the OTC sales guidance it provided in mid-October for the current accounting year: between 780 and 800 million euro.

### **Omega Pharma, a pure OTC play**

Since its creation in 1987, Omega Pharma has grown into a multinational group with almost 2,000 staff and with operations in 30 countries spread over Western, Central, and Eastern Europe. Omega Pharma is one of the few pure OTC companies. With its current geographical spread and solid growth, the group is on the way to enter the worldwide Top Ten ranking in the market for over-the-counter medicines and personal care products. The group has the ambition to become a world OTC player over time.

**Conference call.** The management of Omega Pharma (OTC) will comment on the news presented in this press release in a conference call scheduled to start at 6:15 PM CET today. To participate in this conference call, please dial 00 32/2/289 53 11. You can also **download the presentation** that will be used at the conference call from our Web site [www.omega-pharma.be](http://www.omega-pharma.be). An audio-tape of the conference call will be made available following its completion by dialling the same dial-in number).

Disclaimer: This press release contains forward-looking information which is based on current internal estimates and expectations as well as market expectations. Forward-looking statements contain inherent risks and apply exclusively on the date they are made. The actual results may differ substantially from those included in the forward-looking statements.